Navigation Links
GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: 'Promoting Innovation and Access to Life-Saving Medicine Act'

Hails Legislation as Pro-Patient and Pro-Pharmaceutical Innovation

ARLINGTON, Va., March 11 /PRNewswire/ -- The Generic Pharmaceutical Association (GPhA) released the following statement today from GPhA President and CEO Kathleen Jaeger regarding the introduction of H.R. 1427, the Bipartisan Biogenerics Consensus Bill: "Promoting Innovation and Access to Life-Saving Medicine Act."

"For the countless patients who are unable to afford the biopharmaceutical medicines they desperately need, today's bipartisan introduction of the 'Promoting Access to Life-Saving Medicine Act' provides great hope that they will soon be able to obtain high quality care at more affordable costs. We applaud Chairman Henry Waxman (D-CA) and Rep. Nathan Deal (R-GA), Rep. Frank Pallone (D-NJ) and Rep. Jo Ann Emerson (R-MO) for working together to introduce this consensus bill that achieves the balance of fostering pharmaceutical innovation while also making affordable medicines available to consumers. And we look forward to the bipartisan introduction of a companion bill in the Senate in the near future.

"As our nation acts to strengthen our health care system, our priority must be to reduce costs while increasing access to quality care. Studies continue to show that creating a workable biogenerics approval pathway will not only bring life-saving medicines to patients in need, it will also save our health care system billions of dollars.

"That's why consumer, business and labor organizations, AARP and many of our nation's governors support legislation that brings biogeneric medicines to consumers sooner rather than later through timely resolution of patent disputes and market exclusivity provisions consistent with the Hatch-Waxman model. Over the past two years, members of Congress have learned a great deal about biogenerics. They've heard from the FDA that the science exists to approve safe, effective and affordable biogenerics. They've heard that the FDA scientists want the authority and flexibility to determine how to best ensure safety and efficacy. And they've heard that significant cost savings will result from bringing biogenerics to consumers.

"This bipartisan bill recognizes our health care system's successful experience with generic medicines for the past 25 years. The market exclusivity provisions in Hatch-Waxman have clearly demonstrated that we can achieve the much-needed balance between pharmaceutical competition and innovation for the benefit of consumers, payors and state and federal governments. We've done it before with generics and we can do it again with biogenerics.

"Now, it's time for action. Now, more than ever, it's time to put patients first.

"During these difficult economic times, there must be increased urgency to support solutions that strengthen health care while reducing costs. 'The Promoting Innovation and Access to Life-Saving Medicine Act' is the right solution for high quality care at affordable costs."

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 69% of the total prescriptions dispensed in the United States, but only 16% of all dollars spent on prescription drugs. For more information on biogenerics, please log on to

SOURCE Generic Pharmaceutical Association (GPhA)
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. CV Therapeutics Statement on Unsolicited Proposal From Astellas
2. Sinovac Releases Statement on Healive Vaccine Suspension
3. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
4. Extraordinary General Meetings Statement - XTL Notifies NASDAQ of Compliance with Marketplace Rule 4350(d)(2)
5. Resverlogix Issues a Management Statement
6. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
7. Jazz Pharmaceuticals Files Form S-3 Registration Statements
8. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
9. Statement from Lighthouse International About the Study on Gene Therapy Concerning Lebers Congenital Amaurosis
10. Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI With Regard to Patents Held by AGA Medical
11. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... AxioMx ... that it has received a Phase I Small Business Innovative Research (SBIR) grant ... of General Medical Sciences (NIGMS), will fund the development of a technique to ...
(Date:10/13/2015)... , October 13, 2015 ... and development company, has entered into a strategic relationship ... and Paris, France ... --> --> This collaborative arrangement gives ... respected scientific advisory team as well as long established ...
(Date:10/13/2015)... YORK , Oct. 13, 2015  According ... laboratory services will reach $102 billion by the ... part of the health industry, as it is ... a result of laboratory tests. In addition to ... performed to evaluate disease progression, monitor drug treatment ...
(Date:10/13/2015)... ... October 13, 2015 , ... Exotic Automation ... handling solutions and components, is opening its latest Parker Store retail location in ... is Exotic’s second major expansion in Metropolitan Detroit in less than a year. ...
Breaking Biology Technology:
(Date:9/29/2015)... excited to be named one of the first 100 IBM ... was recently made at an invite-only IBM Watson: Fueling ... , where iDAvatars presented a demo of its Intelligent ... is both an honor and a privilege to be one ... cognitive power of IBM Watson in our product, which empowers ...
(Date:9/28/2015)... -- According to a new market research ... & Others), Application (Access Control & Others), Industry (Travel ... Global - Forecast to 2020", published by MarketsandMarkets, the Iris ... by 2020, at a CAGR of 23.40% between 2015 ... T ables and 66 Figures spread ...
(Date:9/24/2015)... Publiceringsförbud fram till: ... Kerv ( ), det Londonbaserade ... första kontaktlösa betalningsring på i ett ... för massproduktion via crowdfunding.       ... Kerv-bärare kan göra direkta kontaktlösa betalningar ...
Breaking Biology News(10 mins):